Zuhoor Elham Ltd

Zuhoor Elham Ltd is a pharmaceutical importer based in Pakistan, specializing in the procurement of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company plays a pivotal role in Pakistan's pharmaceutical distribution network, ensuring the availability of essential medications across various therapeutic categories. While specific details about its parent company and exact headquarters location are not publicly disclosed, Zuhoor Elham Ltd's operations are integral to the healthcare supply chain in Pakistan.

Zuhoor Elham Ltd's distribution network encompasses multiple warehouse locations strategically situated to facilitate efficient logistics and timely delivery of pharmaceutical products throughout Pakistan. The company's logistics capabilities are robust, enabling it to manage a diverse portfolio of imported medications. Geographically, Zuhoor Elham Ltd's reach extends across Pakistan, ensuring that both urban and rural areas have access to essential pharmaceutical products.

In Pakistan's pharmaceutical supply chain, Zuhoor Elham Ltd functions primarily as a wholesaler and importer. By sourcing finished pharmaceutical formulations from international suppliers, the company bridges the gap between global manufacturers and the local market, ensuring the availability of a wide range of medications to meet the country's healthcare needs.

Zuhoor Elham Ltd demonstrates a high degree of supplier concentration, sourcing the majority of its pharmaceutical imports from a single supplier, MACLEODS PHARMACEUTICALS LIMITED. This single-source dependency could pose risks related to supply chain disruptions, such as production delays or quality control issues. However, the consistent volume of shipments and the substantial total import value suggest a stable and well-established relationship between Zuhoor Elham Ltd and MACLEODS PHARMACEUTICALS LIMITED. The company's portfolio concentration, with the top five products accounting for 100% of imports, further indicates a focused sourcing strategy.

The resilience of Zuhoor Elham Ltd's supply chain is closely tied to its reliance on MACLEODS PHARMACEUTICALS LIMITED. The absence of backup suppliers and the limited diversity in imported formulations may expose the company to risks if disruptions occur with this primary supplier. Additionally, the concentration of shipments through specific ports, such as Nhava Sheva, could impact the supply chain's flexibility. Ensuring that MACLEODS PHARMACEUTICALS LIMITED adheres to international regulatory standards and maintains robust quality control measures is crucial for mitigating potential supply chain vulnerabilities.

Zuhoor Elham Ltd's sourcing pattern, characterized by a concentrated supplier base and a focused product portfolio, positions the company to leverage strong relationships with its primary supplier. This strategy may lead to favorable terms and consistent product quality. For Indian exporters, understanding Zuhoor Elham Ltd's specific product requirements and quality standards is essential to explore opportunities for becoming alternative suppliers, thereby diversifying the company's supply chain and reducing potential risks associated with single-source dependency.

The Drug Regulatory Authority of Pakistan (DRAP) is the primary regulatory body overseeing the pharmaceutical sector in Pakistan. Established under the DRAP Act of 2012, DRAP is responsible for ensuring the quality, safety, and efficacy of therapeutic goods, including pharmaceuticals. The Drugs Act of 1976 provides the legal framework for the regulation of drugs in Pakistan, encompassing aspects such as manufacturing, import, export, and distribution. The Import and Export of Therapeutic Goods Rules, 2026, further delineate the procedures and requirements for importing and exporting pharmaceutical products, ensuring compliance with national standards. (dra.gov.pk)

Importers of pharmaceutical products in Pakistan must obtain a Drug Import License (D.I.L.) from DRAP. The application process involves submitting requisite documents through DRAP's online portal, with a typical processing timeline of five days. Additionally, an Import Clearance Certificate is required for each shipment of finished drugs, ensuring that imported products meet the prescribed standards of quality, safety, and efficacy. Compliance with Good Manufacturing Practices (GMP) is mandatory for both domestic and international manufacturers. DRAP recognizes GMP certifications from reputable authorities, including the European Union (EU), World Health Organization (WHO), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S), facilitating the importation of quality pharmaceutical products. (dra.gov.pk)

Imported pharmaceutical products must undergo batch testing to verify their quality and compliance with DRAP's standards. Stability requirements are enforced to ensure that products maintain their efficacy and safety throughout their shelf life. Labeling must be in accordance with the Drugs (Labeling and Packaging) Rules, 1986, which stipulate that all imported packaged medicines display the name and prescription material in the local language. Serialization mandates are in place to enhance traceability and prevent counterfeit products from entering the market.

In March 2026, DRAP published the draft Therapeutic Goods (Import and Export) Rules, 2026, for public consultation. These proposed rules aim to streamline the import and export procedures for therapeutic goods, including pharmaceuticals, and are expected to come into force upon finalization. The draft rules emphasize compliance with international standards and aim to enhance the efficiency of regulatory processes. (dra.gov.pk)

Zuhoor Elham Ltd's product strategy focuses on therapeutic areas with high demand in Pakistan, including respiratory, advanced antibiotics, and gastrointestinal categories. The company's imports of prednisolone, linezolid, domperidone, folic acid, and omega-3 supplements align with these therapeutic areas, indicating a strategic approach to meet the healthcare needs of the population. The substantial import values of these products reflect their critical importance in the local market.

Zuhoor Elham Ltd's sourcing strategy is centered on generic pharmaceutical products, primarily sourced from India. The company's preference for finished pharmaceutical formulations, as opposed to raw active pharmaceutical ingredients (APIs), suggests a focus on ready-to-market products that can be swiftly distributed within Pakistan. India's established pharmaceutical manufacturing capabilities and competitive pricing make it a favorable sourcing destination for Zuhoor Elham Ltd.

Based on its product mix, Zuhoor Elham Ltd serves a broad segment of the Pakistani pharmaceutical market, including retail pharmacies, hospitals, and wholesale distribution channels. The company's focus on essential medications across various therapeutic categories positions it as a key player in meeting the diverse healthcare needs of the population.

There is a realistic opportunity for new Indian suppliers to collaborate with Zuhoor Elham Ltd, especially in therapeutic areas where the company seeks to diversify its product offerings. Identifying gaps in the current sourcing strategy, such as the need for additional suppliers or alternative formulations, can provide avenues for new entrants to establish partnerships. However, any new supplier must meet DRAP's regulatory requirements and quality standards to be considered a viable partner.

Indian exporters aiming to supply pharmaceutical products to Zuhoor Elham Ltd and the broader Pakistani market must obtain GMP certifications recognized by DRAP, such as those from the EU, WHO, or PIC/S. Additionally, compliance with DRAP's import licensing requirements, including obtaining a Drug Import License and Import Clearance Certificates, is mandatory. Adherence to labeling and packaging regulations, as outlined in the Drugs (Labeling and Packaging) Rules, 1986, is also essential. (dra.gov.pk)

To establish a relationship with Zuhoor Elham Ltd, Indian exporters should first ensure compliance with DRAP's regulatory requirements, including obtaining the necessary certifications and licenses. Engaging in direct communication with Zuhoor Elham Ltd to understand their specific product needs and quality expectations is crucial. Participating in relevant tenders and industry events can provide opportunities to showcase products and build rapport. Developing a clear regulatory filing strategy and understanding the expected timelines for approval processes will facilitate smoother collaboration.